Europeiska unionen - litauiska - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumabas - išsėtinė sklerozė - selektyvūs imunosupresantai - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ir 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Europeiska unionen - litauiska - EMA (European Medicines Agency)

sandoz gmbh - natalizumabas - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresantai - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ir 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Europeiska unionen - litauiska - EMA (European Medicines Agency)

elan pharma international ltd. - natalizumabas - krono liga - immunostimulants, - gydymas vidutiniškai labai aktyvus krono liga mažinti, požymiai ir simptomai, ir indukciją, ir priežiūra patyrė atsako ir remisija, pacientams, kurie nebuvo atsakyta nepaisant visišką ir tinkamą gydymo kursas su kortikosteroidų ir immunosuppressant; arba netoleruoja arba turėti medicininių kontraindikacijų, kad tokios terapijos.

Europeiska unionen - litauiska - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetilfumaratas - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Litauen - litauiska - SMCA (Valstybinė vaistų kontrolės tarnyba)

norameda, uab - fingolimodas - kietosios kapsulės - 0,5 mg - fingolimod

Europeiska unionen - litauiska - EMA (European Medicines Agency)

mylan ireland limited - dimetilfumaratas - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Europeiska unionen - litauiska - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetilfumaratas - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Litauen - litauiska - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - dimetilfumaratas - skrandyje neirios kietosios kapsulės - 120 mg - dimethyl fumarate

Litauen - litauiska - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - dimetilfumaratas - skrandyje neirios kietosios kapsulės - 240 mg - dimethyl fumarate

Europeiska unionen - litauiska - EMA (European Medicines Agency)

teva gmbh - dimetilfumaratas - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresantai - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).